Editorial
|
|
|
|
|
The long fight against drug-price speculation, fatalistic attitudes and insufficient funding must go on
|
|
|
|
Marketing Authorisations
|
|
|
|
|
More life-threatening adverse events
|
|
|
|
|
|
|
|
|
|
No noteworthy advantage for preventing exacerbations
|
|
|
|
|
|
|
|
|
|
Continue to use metronidazole
|
|
|
|
|
|
|
|
|
|
No better than other immunosuppressants
|
|
|
|
|
|
|
|
|
|
More harmful than beneficial
|
|
|
|
|
|
|
|
|
|
|
|
A poorly effective and excessively toxic antibiotic
|
|
|
|
|
|
|
|
|
|
Do not use this combination
|
|
|
|
|
|
Adverse Effects
|
|
|
|
|
Different adverse effect profiles
|
|
|
|
|
|
|
|
|
|
Discovered after decades of use
|
|
|
|
|
|
|
|
|
|
Taking into account risk factors
|
|
|
|
Reviews
|
|
|
|
|
Evaluation results too heterogeneous to justify exposing women and children to these drugs
|
|
|
|
Outlook
|
|
|
|
|
Interaction between human error and IT design flaws
|
|
|
|
|
|
|
|